Navigation Links
Shire Regenerative Medicine Initiates Phase 3 Study of ABH001 for Patients with Epidermolysis Bullosa
Date:2/8/2013

d party contractors for certain goods and services, and any inability of these third party manufacturers to manufacture products, or any failure of these third party contractors to provide these goods and services, in each case in accordance with its respective contractual obligations, could adversely affect Shire's ability to manage its manufacturing processes or to operate its business;
  • the development, approval and manufacturing of Shire's products is subject to extensive oversight by various regulatory agencies and regulatory approvals or interventions associated with changes to manufacturing sites, ingredients or manufacturing processes could lead to significant delays, increase in operating costs, lost product sales, an interruption of research activities or the delay of new product launches;
  • the actions of certain customers could affect Shire 's ability to sell or market products profitably and fluctuations in buying or distribution patterns by such customers could adversely impact Shire's revenues, financial conditions or results of operations;
  • investigations or enforcement action by regulatory authorities or law enforcement agencies relating to Shire's activities in the highly regulated markets in which it operates may result in the distraction of senior management, significant legal costs and the payment of substantial compensation or fines;
  • adverse outcomes in legal matters and other disputes, including Shire's ability to obtain, maintain, enforce and defend patents and other intellectual property rights required for its business, could have a material adverse effect on Shire's revenues, financial condition or results of operations;
  • and other risks and uncertainties detailed from time to time in Shire's filings with the U.S. Securities and Exchange Commission, including its most recent Annual Report on Form 10-K.

    i. Fine J-D, Johnson  LB, Suchindran C, Gedde-DahI T (1999e) The Epidemiology of I
    '/>"/>

    SOURCE Shire plc
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6

    Related biology technology :

    1. Shire to Acquire FerroKin BioSciences, Inc., and its Phase 2 Iron Chelator Treatment
    2. Heptares Grants Shire an Exclusive Worldwide Licence to Develop and Commercialise Novel Drug Candidate for CNS Disorders
    3. Shire plc: First Quarter 2012 Results Date Notification - April 26, 2012
    4. Shire Facebook Page Increases Awareness of Hereditary Angioedema (HAE) in Support of First HAE Awareness Day May 16th
    5. Berkshire Corporation Offers Live Chat For Americas Website and Shopping Cart
    6. Shire Changes its NASDAQ Ticker Symbol to SHPG
    7. Dr. Jeff Jonas Appointed President of Shire Regenerative Medicine Business and Joins Shire Leadership Team
    8. Shire and Boston Childrens Hospital Enter Into Broad Research Collaboration
    9. Shire Reaches Agreement in Principle With U.S. Government
    10. Palm Beach Residents to Learn How the Future of Regenerative Medicine Will Combat Aging
    11. ODT Forum Presents Regenerative Technologies
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:5/26/2015)... May 26, 2015  Sangamo BioSciences, Inc. (NASDAQ: SGMO ... and CEO, will provide an update on the progress of ... of the company,s business strategy at 1:30pm ET on Monday, ... The conference is being held in New York, ... live and may be accessed via a link on the ...
    (Date:5/26/2015)... 2015 Global Stem Cells Group ... for the company’s first cellular and regenerative medicine symposium ... full day, hands-on stem cell training class Oct. 10. ... Gimenez, M.D., President of Therapeutic Confrontations (CONFTERA) in Barcelona. ... interest in regenerative medicine and recent advances in cellular ...
    (Date:5/26/2015)... , May 26, 2015 Pharmaco-Kinesis Corporation (PKC) ... recently convened at Shutters on the Beach in ... development status of the Company,s innovative Metronomic Biofeedback Pump ... locally deliver chemotherapy over time to a target site ... capacity and biofeedback system in real-time.  ...
    (Date:5/26/2015)... , May 26, 2015  Asterias Biotherapeutics, Inc. ... emerging field of regenerative medicine, today announced that all ... 2014 were exercised prior to their expiry on June ... of $11.7 million. "We thank our shareholders ... President and CEO of Asterias. "This exercise of warrants ...
    Breaking Biology Technology:Sangamo BioSciences Announces Presentation At The Jefferies 2015 Global Healthcare Conference 2Stem Cell Training, Inc. Announces First European Symposium on Cellular and Regenerative Medicine 2Stem Cell Training, Inc. Announces First European Symposium on Cellular and Regenerative Medicine 3Pharmaco-Kinesis Corporation Convenes Third Neuro-Oncology Clinical Advisory Board Meeting 2Pharmaco-Kinesis Corporation Convenes Third Neuro-Oncology Clinical Advisory Board Meeting 3Pharmaco-Kinesis Corporation Convenes Third Neuro-Oncology Clinical Advisory Board Meeting 4Pharmaco-Kinesis Corporation Convenes Third Neuro-Oncology Clinical Advisory Board Meeting 5Asterias Biotherapeutics Receives $11.7 Million in Proceeds from Exercise of Warrants 2Asterias Biotherapeutics Receives $11.7 Million in Proceeds from Exercise of Warrants 3
    (Date:5/5/2015)... , May 5, 2015, NXT-ID, Inc. (NASDAQ: ... company focused on the growing mobile commerce market, reminds investors ... Chief Technology Officer, is presenting  at CARTES SECURE CONNEXIONS AMERICA ... 5-7, 2015. The three-day conference is organized ... is speaking in is themed Global Fraud: Where is ...
    (Date:4/20/2015)... Huntington Memorial Hospital is the first facility ... miniaturized, wireless monitoring sensor to manage heart failure (HF). ... FDA-approved heart failure monitoring device that has been proven ... to manage heart failure. The CardioMEMS HF ... pulmonary artery (PA) during a non-surgical procedure to directly ...
    (Date:4/13/2015)... 2015 According to a ... Market Forecast & Opportunities, 2020", the global biometrics market ... 14% till 2020. The biometrics market is garnering ... and review of biometric management systems. The constant ... with greater efficiency, are resulting in increasing installation ...
    Breaking Biology News(10 mins):NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 2NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 3Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 2Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 3Global Biometrics Market to Cross US$ 21 Billion by 2020: TechSci Research 2
    ... researchers and a colleague from India unveiled a new ... was presented at the 63rd annual meeting of the ... The cancer treatment uses hyperthermia to elevate the ... tissue at a lower degree of body heat. The ...
    ... clocks adjust to having less sunlight in the winter could help ... Scientists studying the daily activity cycle in plants known ... enables the plant,s genes to respond to the times of dawn ... in between. This system helps the plant to reset its ...
    ... engineering researchers in the University of Minnesota,s College of ... at higher temperatures may be an effective tool in ... solid waste to 130 degrees Fahrenheit (55 degrees Celsius) ... antibiotic resistance. These genes are used by bacteria to ...
    Cached Biology News:Virginia Tech engineers introduce thermotherapy as a chemotherapy alternative 2University of Minnesota engineering researcher finds new way to fight antibiotic-resistant bacteria 2
    ... The Neural Stem Cell Expansion Kit - ... vitro neural stem cell expansion as neurospheres ... a specially formulated N-2 Plus Media Supplement, which ... (Johe, K.K. et al . (1996) Genes ...
    ... thymus Description: Topoisomerase I relaxes both ... breakage and rejoining of phosphodiester bonds (1,2) . ... to be differentiated by a single nucleotide pair ... active in the absence of Mn 2+ ...
    ... I, Wild Type Liquid. In 100 ... 200 µM EDTA, 20% glycerol, pH 7.9. AVOID ... is a monomeric protein of 765 amino acids ... relaxation of both positive and negative supercoiled DNAs ...
    DNA polymerase I, large fragment...
    Biology Products: